Bruker Corporation (Billerica, Massachusetts, USA) and Biognosys AG (Schlieren, Switzerland) have announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys.
Co-founder and CEO Oliver Rinner and his leadership team will continue to manage Biognosys as a proteomics and proteogenomics contract research organization (CRO) services and proteomics software company. Going forward, Biognosys’ biomarker and biopharma customers will be able to access additional services in the US. Biognosys mass spectrometry‑based proteomics solutions help CRO services and proteomics software customers uncover connections between genome, transcriptome, and phenotype and
explore disease biology.
Rinner commented, “We are pleased to partner with Bruker to leverage our unique synergies to enable customers to explore the depth of the proteome from early research to clinical development.”
Rohan Thakur, president of the Bruker Life-Science Mass Spectrometry division, said, “We are delighted to partner with Biognosys to expand our CRO business in the US. We have many common biomarker and biopharma customers, and even more potential customers may prefer a proteomics CRO services expert like Biognosys for rapid, highest quality and flexible insertion of proteomics into their biomarker or biopharma discovery and development.”
Professor emeritus and proteomics pioneer Ruedi Aebersold added, “For over a decade, ETH spin-off Biognosys has translated novel proteomics methods pioneered in our research group into robust, high-performance workflows for large-scale basic and translational research. I am delighted that this new partnership between Biognosys and Bruker will further accelerate access to high performance proteomics. It will also provide opportunities to develop next-generation technology and methods to determine unexplored but functionally relevant dimensions of the proteome and protein interaction networks as a function of cellular state.”
For more information, please visit www.bruker.com or www.biognosys.com
Inside the Laboratory: The Gionfriddo Group at the University at Buffalo
March 28th 2024In this edition of “Inside the Laboratory,” Emanuela Gionfriddo, PhD, an associate professor of chemistry at the University at Buffalo, discusses her group’s current research endeavors, including using solid-phase microextraction (SPME) coupled to liquid chromatography (LC) and gas chromatography (GC) to further understand the chemical relationship between environmental exposure and disease and elucidate micropollutants fate in the environment and biological systems.
Transferring Methods to Compact and Portable HPLC
February 14th 2024The current trend in laboratory equipment design is the miniaturization of laboratory instruments. Smaller-scale HPLC instruments offer benefits that cannot be matched by analytical-scale equipment, especially in the areas of portability, reduced fluid volumes, and reduced operating costs. Yet, the miniaturization of laboratory equipment has brought with it a unique set of challenges, including transferring methods to compact LC. Capillary LC expands the use of LC to applications not currently done using conventional LC in a wide array of application areas, including pharmaceutical, food and beverage, petrochemical, environmental, and oil and gas. Greg Ward, Axcend’s CEO wrote, “Customers want an HPLC system with a small footprint, low flow rates and green chemistry.” Join his podcast where he shares method transfer in these application areas.